These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 32343209

  • 1. Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis.
    Zhou IY, Clavijo Jordan V, Rotile NJ, Akam E, Krishnan S, Arora G, Krishnan H, Slattery H, Warner N, Mercaldo N, Farrar CT, Wellen J, Martinez R, Schlerman F, Tanabe KK, Fuchs BC, Caravan P.
    Radiology; 2020 Jul; 296(1):67-75. PubMed ID: 32343209
    [No Abstract] [Full Text] [Related]

  • 2. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis.
    Waghorn PA, Ferreira DS, Erstad DJ, Rotile NJ, Masia R, Jones CM, Tu C, Sojoodi M, Chen YI, Schlerman F, Wellen J, Martinez RVP, Tanabe KK, Fuchs BC, Caravan P.
    Sci Rep; 2021 Mar 17; 11(1):6105. PubMed ID: 33731798
    [Abstract] [Full Text] [Related]

  • 3. Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH).
    Hartimath SV, Boominathan R, Soh V, Cheng P, Deng X, Chong YC, Yong FF, Tan PW, Han W, Robins EG, Goggi JL.
    Contrast Media Mol Imaging; 2019 Mar 17; 2019():6298128. PubMed ID: 31866798
    [Abstract] [Full Text] [Related]

  • 4. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V, Bedossa P, Newsome PN.
    Gastroenterology; 2019 May 17; 156(6):1717-1730. PubMed ID: 30689971
    [Abstract] [Full Text] [Related]

  • 5. Gd-EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice.
    Yamada T, Obata A, Kashiwagi Y, Rokugawa T, Matsushima S, Hamada T, Watabe H, Abe K.
    Magn Reson Imaging; 2016 Jul 17; 34(6):724-729. PubMed ID: 26979540
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of a PEGylated Fibroblast Growth Factor 21 Variant Using Novel Preclinical Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Mouse Model of Nonalcoholic Steatohepatitis.
    Tang H, Li J, Zinker B, Boehm S, Mauer A, Rex-Rabe S, Glaser KJ, Fronheiser M, Bradstreet T, Nakao Y, Petrone T, Pena A, Villano M, Chow P, Malhi H, Charles ED, Hayes W, Ehman RL, Du S, Yin M.
    J Magn Reson Imaging; 2022 Sep 17; 56(3):712-724. PubMed ID: 35092323
    [Abstract] [Full Text] [Related]

  • 7. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L, Ferolla SM, Lima AS, Vidigal PVT, Ferrari TCA.
    Eur J Radiol; 2018 Jan 17; 98():82-89. PubMed ID: 29279175
    [Abstract] [Full Text] [Related]

  • 8. Visco-Elastic Parameters at Three-Dimensional MR Elastography for Diagnosing Non-Alcoholic Steatohepatitis and Substantial Fibrosis in Mice.
    Khalfallah M, Doblas S, Hammoutene A, Julea F, Postic C, Valla D, Paradis V, Garteiser P, Van Beers BE.
    J Magn Reson Imaging; 2024 Jan 17; 59(1):97-107. PubMed ID: 37158252
    [Abstract] [Full Text] [Related]

  • 9. Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis.
    Tølbøl KS, Stierstorfer B, Rippmann JF, Veidal SS, Rigbolt KTG, Schönberger T, Gillum MP, Hansen HH, Vrang N, Jelsing J, Feigh M, Broermann A.
    Dig Dis Sci; 2019 May 17; 64(5):1238-1256. PubMed ID: 30511198
    [Abstract] [Full Text] [Related]

  • 10. Molecular MR Imaging of Myeloperoxidase Distinguishes Steatosis from Steatohepatitis in Nonalcoholic Fatty Liver Disease.
    Pulli B, Wojtkiewicz G, Iwamoto Y, Ali M, Zeller MW, Bure L, Wang C, Choi Y, Masia R, Guimaraes AR, Corey KE, Chen JW.
    Radiology; 2017 Aug 17; 284(2):390-400. PubMed ID: 28358240
    [Abstract] [Full Text] [Related]

  • 11. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort.
    Imajo K, Tetlow L, Dennis A, Shumbayawonda E, Mouchti S, Kendall TJ, Fryer E, Yamanaka S, Honda Y, Kessoku T, Ogawa Y, Yoneda M, Saito S, Kelly C, Kelly MD, Banerjee R, Nakajima A.
    World J Gastroenterol; 2021 Feb 21; 27(7):609-623. PubMed ID: 33642832
    [Abstract] [Full Text] [Related]

  • 12. Assessment of Nonalcoholic Fatty Liver Disease in Rats Using Quantitative Dynamic Contrast-Enhanced MRI.
    Wu Z, Cheng ZL, Yi ZL, Xie MW, Zeng H, Lu LJ, Xu X, Shen J.
    J Magn Reson Imaging; 2017 May 21; 45(5):1485-1493. PubMed ID: 27606822
    [Abstract] [Full Text] [Related]

  • 13. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M.
    World J Gastroenterol; 2018 Jan 14; 24(2):179-194. PubMed ID: 29375204
    [Abstract] [Full Text] [Related]

  • 14. The Role of Multiparametric US of the Liver for the Evaluation of Nonalcoholic Steatohepatitis.
    Sugimoto K, Moriyasu F, Oshiro H, Takeuchi H, Abe M, Yoshimasu Y, Kasai Y, Sakamaki K, Hara T, Itoi T.
    Radiology; 2020 Sep 14; 296(3):532-540. PubMed ID: 32573385
    [Abstract] [Full Text] [Related]

  • 15. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A, GOLDEN-505 Investigator Study Group.
    Gastroenterology; 2016 May 14; 150(5):1147-1159.e5. PubMed ID: 26874076
    [Abstract] [Full Text] [Related]

  • 16. Can Elastography Differentiate Isolated Fatty Liver from Nonalcoholic Steatohepatitis?
    Ajmera V, Loomba R.
    Semin Liver Dis; 2018 Feb 14; 38(1):14-20. PubMed ID: 29471562
    [Abstract] [Full Text] [Related]

  • 17. Diagnostic value of MR-based texture analysis for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).
    Cannella R, Borhani AA, Tublin M, Behari J, Furlan A.
    Abdom Radiol (NY); 2019 May 14; 44(5):1816-1824. PubMed ID: 30788556
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of hepatic function using dynamic contrast-enhanced magnetic resonance imaging in melanocortin 4 receptor-deficient mice as a model of nonalcoholic steatohepatitis.
    Yamada T, Kashiwagi Y, Rokugawa T, Kato H, Konishi H, Hamada T, Nagai R, Masago Y, Itoh M, Suganami T, Ogawa Y, Abe K.
    Magn Reson Imaging; 2019 Apr 14; 57():210-217. PubMed ID: 30465867
    [Abstract] [Full Text] [Related]

  • 19. Gd-EOB-DTPA-enhanced T1ρ imaging vs diffusion metrics for assessment liver inflammation and early stage fibrosis of nonalcoholic steatohepatitis in rabbits.
    Xie Y, Zhang H, Jin C, Wang X, Wang X, Chen J, Xu Y.
    Magn Reson Imaging; 2018 May 14; 48():34-41. PubMed ID: 29278765
    [Abstract] [Full Text] [Related]

  • 20. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
    Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H, Fujita K, Yoneda M, Taguri M, Hyogo H, Sumida Y, Ono M, Eguchi Y, Inoue T, Yamanaka T, Wada K, Saito S, Nakajima A.
    Gastroenterology; 2016 Mar 14; 150(3):626-637.e7. PubMed ID: 26677985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.